PFSF-logo-3

 

Aug. 1, 2013

 

Dear Friends:

When we incorporated the Post-Finasteride Syndrome Foundation in July 2012, our mission was clear:

To fund research on the characterization, underlying biologic mechanisms and treatments of PFS while raising public awareness of this often life-altering condition afflicting thousands of men the world over.

Now, on the occasion of our one-year anniversary, I’m pleased to report that we’ve not only stayed that course but made more headway than we’d hoped.

Here are a few of the key milestones the foundation has achieved in 12 short months:

  • Development: Thanks to generous contributions from hundreds of donors around the globe – from Bethlehem, Pennsylvania, to Melbourne, Australia – we’ve raised hundreds of thousands of dollars in funding.
  • Tax-Exempt Status: In March, we were granted retroactive 501(c)(3) status by the Internal Revenue Service as a public charity, so that all donations made during the past year are tax-deductible in the United States.
  • Research: On July 1, we announced the funding of a major clinical study on PFS at Boston’s Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School. In the coming weeks, we’ll announce the funding of a second, complementary study at another major medical institution.
  • Education: In February, we sponsored a roundtable discussion on PFS at the University of Milan’s 7th International Meeting on Steroids and the Nervous System conference in Torino, Italy. We’ll be involved in similar efforts within academic circles this fall.

I’m also pleased to report that the foundation intends to continue this important work, which promises to lead to a better understanding of PFS, and perhaps the development of effective medical treatments in the coming years.

And while I’m writing today to thank donors for their contributions over the past year, I’m also asking that all visitors to PFSFoundation.org give generously to the foundation, so that we can continue this important work.

Sincerely,

John-Santmann-signature-psd-4

John Santmann, MD
CEO

 

PFSF-address2